Augmentin Indications and Approved Uses

When clinicians choose it in pediatrics

Augmentin is a trusted antibiotic that helps children fight bacterial infections. Understanding when and how it's used ensures your child receives the right treatment at the right time for their infection.

Looking for the dose calculator or main medication overview? Return to the main Augmentin page.

Primary FDA-Approved Indications

Augmentin is widely used in pediatric practice for resistant infections, sinusitis, pneumonia, skin infections. It is labeled from birth: infants under 12 weeks get 30 mg/kg/day of the amoxicillin component divided every 12 hours using the 125 mg/5 mL suspension; older children typically get 25-45 mg/kg/day divided every 12 hours, and the ES-600 suspension is used for 90 mg/kg/day high-dose plans (label). Clinical evidence supports its safety and efficacy when used as directed.

Recurrent or Treatment-Resistant Otitis Media

FDA Approved

Infants ≥6 months and childrenLevel A (Multiple RCTs)Second-lineFDA ApprovedOtherICD-10: R69

Used as a second-line option in children who have not improved after 48–72 hours of amoxicillin or have received amoxicillin in the past 30 days

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Recurrent or Treatment-Resistant Otitis Media Treatment Guidelines(2023)

Acute Bacterial Sinusitis

FDA Approved

Toddlers and older childrenLevel A (Multiple RCTs)First-lineFDA ApprovedRespiratoryICD-10: J32.9

Preferred in children with moderate to severe symptoms or suspected beta-lactamase–producing organisms; Augmentin is first-line in guidelines for pediatric bacterial sinusitis

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Acute Bacterial Sinusitis Treatment Guidelines(2023)

Community-Acquired Pneumonia (Non-Atypical)

FDA Approved

Infants >3 months and school-aged childrenLevel A (Multiple RCTs)Second-lineFDA ApprovedOtherICD-10: J18.9

Useful when typical pathogens like *H. influenzae* or beta-lactamase–producing strains are suspected or confirmed, especially in children with recent antibiotic exposure

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Community-Acquired Pneumonia (Non-Atypical) Treatment Guidelines(2023)

Secondary Clinical Uses

Skin and Soft Tissue Infections (e.g., Impetigo, Cellulitis)

Secondary Use

Children of all ages as clinically indicatedLevel B (Single RCT or large non-randomized)First-lineFDA ApprovedSkinICD-10: R69

Effective against common skin pathogens including *Staphylococcus aureus* (non-MRSA) and *Streptococcus pyogenes*; often chosen for bite wounds due to polymicrobial coverage

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Skin and Soft Tissue Infections (e.g., Impetigo, Cellulitis) Treatment Guidelines(2023)

Human or Animal Bite Wounds

Secondary Use

Children of all ages as indicatedLevel B (Single RCT or large non-randomized)First-lineFDA ApprovedOtherICD-10: R69

Recommended for bite-related infections due to its activity against anaerobes and other mixed flora, including *Pasteurella* species

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Human or Animal Bite Wounds Treatment Guidelines(2023)

Urinary Tract Infections (Selected Cases)

Secondary Use

Toilet-trained children and adolescentsLevel B (Single RCT or large non-randomized)Second-lineFDA ApprovedGUICD-10: N39.0

Used when oral treatment is indicated and local resistance patterns permit; active against many strains of *E. coli* and other uropathogens producing beta-lactamase

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Urinary Tract Infections (Selected Cases) Treatment Guidelines(2023)

Off-Label Uses

Note: Off-label uses may be clinically appropriate based on evidence and expert consensus, but are not FDA-approved for these indications. Always consider the evidence base and document clinical reasoning.

Periorbital (Preseptal) Cellulitis Treated as Outpatient

Off-Label

Children ≥1 year who appear well and have no orbital involvementLevel B (Single RCT or large non-randomized)First-lineOff-LabelHEENTICD-10: H00.033

Used when MRSA risk is low and imaging/ophthalmology confirm disease is limited to the eyelid. Covers *Streptococcus* and beta-lactamase–producing *H. influenzae* and anaerobes from sinus sources.

How to use

Dosing at a glance: 45-90 mg/kg/day (amoxicillin component) divided every 12 hours for 7-10 days; pair with ophthalmology follow-up within 24-48 hours.

Monitoring & follow-up

Parameters:

Vision changes or restricted extraocular movements
Fever curve and eyelid swelling
Ability to tolerate oral therapy

Frequency: Daily caregiver checks; reassess in clinic within 24-48 hours.

Evidence Sources

AAP/AAO Joint Guidance on Preseptal Cellulitis(2023)

Management of Periorbital and Orbital Cellulitis in Children(2022)

Aspiration Pneumonia (Oral Step-Down Therapy)

Off-Label

Children who completed initial IV therapy and can tolerate oral medicationsLevel C (Consensus/expert opinion)Step-down/ContinuationOff-LabelRespiratoryICD-10: J69.0

Provides anaerobic coverage for aspiration events related to neurologic impairment or swallowing dysfunction when metronidazole cannot be used.

How to use

Dosing at a glance: 40 mg/kg/day divided every 8 hours for 7-14 days depending on clinical response. Every-8-hour dosing uses the 4:1 suspensions (125/31.25 or 250/62.5 mg per 5 mL); the 7:1 suspensions are for every-12-hour dosing (label).

Treatment Duration

Standard: 7-10 days after clinical improvement

Special populations: Extend to 14 days in children with chronic lung disease or recurrent aspiration

Monitoring & follow-up

Parameters:

Respiratory status (work of breathing, oxygen needs)
Hydration and GI tolerance
Signs of hepatic dysfunction when combined with other hepatically cleared agents

Frequency: Clinic or telehealth check within 72 hours; sooner if respiratory symptoms worsen.

Evidence Sources

IDSA Pediatric Pneumonia Recommendations(2023)

Oral Step-Down Strategies for Pediatric Aspiration Pneumonia(2024)

Clinical Decision Support

Quick Selection Guide

Symptom Cluster 1

Symptoms:

Primary symptoms
Associated findings

Likely Diagnosis:

Recurrent or Treatment-Resistant Otitis Media

Action:

Initiate Augmentin therapy

Symptom Cluster 2

Symptoms:

Primary symptoms
Associated findings

Likely Diagnosis:

Acute Bacterial Sinusitis

Action:

Initiate Augmentin therapy

Symptom Cluster 3

Symptoms:

Primary symptoms
Associated findings

Likely Diagnosis:

Community-Acquired Pneumonia (Non-Atypical)

Action:

Initiate Augmentin therapy

Red Flags & Warnings

Allergic reaction symptoms

Stop medication and seek care

Immediate

No improvement after 72 hours

Re-evaluate diagnosis

Soon

When to Reassess

Timeframe: 48-72 hours

Key criteria to review:

Clinical improvement
Symptom resolution

Next steps: Consider alternative if no improvement

Clinical Pearls

•Augmentin dosing should be weight-based
•Complete full course of treatment
•Culture when possible before starting

Alternative Medication Options

Amoxicillin-Clavulanate

Beta-lactam antibiotic

Treatment failure or resistance

Advantages

Broader spectrum

Disadvantages

More GI effects

Relative efficacy: May be superior for resistant organisms

Cost: More expensive

Parent Communication Guide

When This Medicine Helps

Understanding the Condition

Augmentin treats Recurrent or Treatment-Resistant Otitis Media by fighting bacteria.

Why We Choose This Medicine

We choose Augmentin because it's effective and well-tolerated in children.

What to Expect

Most children improve within 48-72 hours.

Monitoring Your Child

Signs the Medicine is Working:

Symptoms improve
Child feels better
Normal activities resume

When to Contact Your Doctor:

No improvement after: 72 hours

Watch for these warning signs:

High fever
Severe symptoms
New symptoms

What to do: Contact your pediatrician

Common Parent Questions

Can I give with food?

Check specific instructions for your medication.

💡 Ask your pharmacist

Never Use Augmentin For

Viral infections

Antibiotics only work against bacteria

Alternatives: Supportive care

Known allergy to Augmentin

Risk of allergic reaction

Alternatives: Alternative medication

Last updated: 7/21/2025•Evidence quality: 8/10

Back to Overview

References

FDA Approved Labeling for Augmentin2024https://www.accessdata.fda.gov/scripts/cder/daf/
Pediatric Recurrent or Treatment-Resistant Otitis Media Treatment Guidelines2023https://www.aap.org/clinical-guidelines
AAP/AAO Joint Guidance on Preseptal Cellulitis2023https://www.aao.org/clinical-statement
Management of Periorbital and Orbital Cellulitis in Children2022https://pubmed.ncbi.nlm.nih.gov/35278940/
IDSA Pediatric Pneumonia Recommendations2023https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-in-children/
Oral Step-Down Strategies for Pediatric Aspiration Pneumonia2024https://pubmed.ncbi.nlm.nih.gov/38321045/

Peds CalcSimple and Safe Pediatric Dosing Tools

PedsCalc Pro

Get the installable pediatric calculator app.

149 tools, 65 medication dose calculators, local notes, quick history, and a home-screen web app.

Open app Install

Back to Augmentin Overview

Augmentin Indications and Approved Uses

When clinicians choose it in pediatrics

Looking for the dose calculator or main medication overview? Return to the main Augmentin page.

Primary FDA-Approved Indications

Recurrent or Treatment-Resistant Otitis Media

FDA Approved

Infants ≥6 months and childrenLevel A (Multiple RCTs)Second-lineFDA ApprovedOtherICD-10: R69

Used as a second-line option in children who have not improved after 48–72 hours of amoxicillin or have received amoxicillin in the past 30 days

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Recurrent or Treatment-Resistant Otitis Media Treatment Guidelines(2023)

Acute Bacterial Sinusitis

FDA Approved

Toddlers and older childrenLevel A (Multiple RCTs)First-lineFDA ApprovedRespiratoryICD-10: J32.9

Preferred in children with moderate to severe symptoms or suspected beta-lactamase–producing organisms; Augmentin is first-line in guidelines for pediatric bacterial sinusitis

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Acute Bacterial Sinusitis Treatment Guidelines(2023)

Community-Acquired Pneumonia (Non-Atypical)

FDA Approved

Infants >3 months and school-aged childrenLevel A (Multiple RCTs)Second-lineFDA ApprovedOtherICD-10: J18.9

Useful when typical pathogens like *H. influenzae* or beta-lactamase–producing strains are suspected or confirmed, especially in children with recent antibiotic exposure

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Community-Acquired Pneumonia (Non-Atypical) Treatment Guidelines(2023)

Secondary Clinical Uses

Skin and Soft Tissue Infections (e.g., Impetigo, Cellulitis)

Secondary Use

Children of all ages as clinically indicatedLevel B (Single RCT or large non-randomized)First-lineFDA ApprovedSkinICD-10: R69

Effective against common skin pathogens including *Staphylococcus aureus* (non-MRSA) and *Streptococcus pyogenes*; often chosen for bite wounds due to polymicrobial coverage

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Skin and Soft Tissue Infections (e.g., Impetigo, Cellulitis) Treatment Guidelines(2023)

Human or Animal Bite Wounds

Secondary Use

Children of all ages as indicatedLevel B (Single RCT or large non-randomized)First-lineFDA ApprovedOtherICD-10: R69

Recommended for bite-related infections due to its activity against anaerobes and other mixed flora, including *Pasteurella* species

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Human or Animal Bite Wounds Treatment Guidelines(2023)

Urinary Tract Infections (Selected Cases)

Secondary Use

Toilet-trained children and adolescentsLevel B (Single RCT or large non-randomized)Second-lineFDA ApprovedGUICD-10: N39.0

Used when oral treatment is indicated and local resistance patterns permit; active against many strains of *E. coli* and other uropathogens producing beta-lactamase

Efficacy Data

Success rate: 85-95%

Time to improvement: 48-72 hours

Evidence Sources

FDA Approved Labeling for Augmentin(2024)

Pediatric Urinary Tract Infections (Selected Cases) Treatment Guidelines(2023)

Off-Label Uses

Periorbital (Preseptal) Cellulitis Treated as Outpatient

Off-Label

Children ≥1 year who appear well and have no orbital involvementLevel B (Single RCT or large non-randomized)First-lineOff-LabelHEENTICD-10: H00.033

Used when MRSA risk is low and imaging/ophthalmology confirm disease is limited to the eyelid. Covers *Streptococcus* and beta-lactamase–producing *H. influenzae* and anaerobes from sinus sources.

How to use

Dosing at a glance: 45-90 mg/kg/day (amoxicillin component) divided every 12 hours for 7-10 days; pair with ophthalmology follow-up within 24-48 hours.

Monitoring & follow-up

Parameters:

Vision changes or restricted extraocular movements
Fever curve and eyelid swelling
Ability to tolerate oral therapy

Frequency: Daily caregiver checks; reassess in clinic within 24-48 hours.

Evidence Sources

AAP/AAO Joint Guidance on Preseptal Cellulitis(2023)

Management of Periorbital and Orbital Cellulitis in Children(2022)

Aspiration Pneumonia (Oral Step-Down Therapy)

Off-Label

Children who completed initial IV therapy and can tolerate oral medicationsLevel C (Consensus/expert opinion)Step-down/ContinuationOff-LabelRespiratoryICD-10: J69.0

Provides anaerobic coverage for aspiration events related to neurologic impairment or swallowing dysfunction when metronidazole cannot be used.

How to use

Dosing at a glance: 40 mg/kg/day divided every 8 hours for 7-14 days depending on clinical response. Every-8-hour dosing uses the 4:1 suspensions (125/31.25 or 250/62.5 mg per 5 mL); the 7:1 suspensions are for every-12-hour dosing (label).

Treatment Duration

Standard: 7-10 days after clinical improvement

Special populations: Extend to 14 days in children with chronic lung disease or recurrent aspiration

Monitoring & follow-up

Parameters:

Respiratory status (work of breathing, oxygen needs)
Hydration and GI tolerance
Signs of hepatic dysfunction when combined with other hepatically cleared agents

Frequency: Clinic or telehealth check within 72 hours; sooner if respiratory symptoms worsen.

Evidence Sources

IDSA Pediatric Pneumonia Recommendations(2023)

Oral Step-Down Strategies for Pediatric Aspiration Pneumonia(2024)

Clinical Decision Support

Quick Selection Guide

Symptom Cluster 1

Symptoms:

Primary symptoms
Associated findings

Likely Diagnosis:

Recurrent or Treatment-Resistant Otitis Media

Action:

Initiate Augmentin therapy

Symptom Cluster 2

Symptoms:

Primary symptoms
Associated findings

Likely Diagnosis:

Acute Bacterial Sinusitis

Action:

Initiate Augmentin therapy

Symptom Cluster 3

Symptoms:

Primary symptoms
Associated findings

Likely Diagnosis:

Community-Acquired Pneumonia (Non-Atypical)

Action:

Initiate Augmentin therapy

Red Flags & Warnings

Allergic reaction symptoms

Stop medication and seek care

Immediate

No improvement after 72 hours

Re-evaluate diagnosis

Soon

When to Reassess

Timeframe: 48-72 hours

Key criteria to review:

Clinical improvement
Symptom resolution

Next steps: Consider alternative if no improvement

Clinical Pearls

•Augmentin dosing should be weight-based
•Complete full course of treatment
•Culture when possible before starting

Alternative Medication Options

Amoxicillin-Clavulanate

Beta-lactam antibiotic

Treatment failure or resistance

Advantages

Broader spectrum

Disadvantages

More GI effects

Relative efficacy: May be superior for resistant organisms

Cost: More expensive

Parent Communication Guide

When This Medicine Helps

Understanding the Condition

Augmentin treats Recurrent or Treatment-Resistant Otitis Media by fighting bacteria.

Why We Choose This Medicine

We choose Augmentin because it's effective and well-tolerated in children.

What to Expect

Most children improve within 48-72 hours.

Monitoring Your Child

Signs the Medicine is Working:

Symptoms improve
Child feels better
Normal activities resume

When to Contact Your Doctor:

No improvement after: 72 hours

Watch for these warning signs:

High fever
Severe symptoms
New symptoms

What to do: Contact your pediatrician

Common Parent Questions

Can I give with food?

Check specific instructions for your medication.

💡 Ask your pharmacist

Never Use Augmentin For

Viral infections

Antibiotics only work against bacteria

Alternatives: Supportive care

Known allergy to Augmentin

Risk of allergic reaction

Alternatives: Alternative medication

Last updated: 7/21/2025•Evidence quality: 8/10

Back to Overview

References

FDA Approved Labeling for Augmentin2024https://www.accessdata.fda.gov/scripts/cder/daf/
Pediatric Recurrent or Treatment-Resistant Otitis Media Treatment Guidelines2023https://www.aap.org/clinical-guidelines
AAP/AAO Joint Guidance on Preseptal Cellulitis2023https://www.aao.org/clinical-statement
Management of Periorbital and Orbital Cellulitis in Children2022https://pubmed.ncbi.nlm.nih.gov/35278940/
IDSA Pediatric Pneumonia Recommendations2023https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-in-children/
Oral Step-Down Strategies for Pediatric Aspiration Pneumonia2024https://pubmed.ncbi.nlm.nih.gov/38321045/